Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine

BIOLOGICAL2 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

Healthy VolunteersHealthy Volunteers (Meningococcal Infection)Meningococcal Immunization

Phase 3

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

CompletedNCT03691610

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers (Meningococcal Infection)

Start: 2018-10-04End: 2023-10-20Updated: 2024-06-25

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa

CompletedNCT04143061

Sanofi Pasteur, a Sanofi CompanyHealthy Volunteers, Meningococcal Immunization

Start: 2019-12-30End: 2023-01-28Updated: 2025-02-03

Related Papers

Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6–23 months: phase III study (US/Puerto Rico)

Pediatric Research2026-03-06

P-662. Phase III, modified double-blind, randomized, parallel group, active-controlled, multi-center study of Meningococcal quadrivalent ACWY conjugated vaccine in infants from 6 through 23 months of age in the United States

Open Forum Infectious Diseases2025-01-29